New cell therapy tested for Tough-to-Treat cancers
NCT ID NCT07242417
Summary
This early-stage study is testing a new cell therapy called TC-G203 for people with advanced solid tumors that have returned or spread. The main goal is to find the safest dose and see how well the body handles the treatment. It is for patients whose cancer has a specific marker (GPC3) and who have already tried other standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Email: •••••@•••••
-
GoBroad Healthcare Group
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.